Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Charles J Gill

Haifeng Tang

Fa-Xiang Ding

Jing Su

John P Caldwell

Christina B Madsen-Duggan

Ginny Dai Ho

Marc A Labroli

Sookhee Nicole Ha

Mihir Mandal

Shu-Wei Yang

Christine Yang

Zheng Tan

Terry Roemer

Christopher Michael Tan

Sandra J Koseoglu

Sang Ho Lee

Hao Wang

Reynalda De Jesus

Jesse J Jackson

Lynn L Silver

Karen L Dorso

Joyce Kohler

Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a &#x3b2;-lactam antibiotic.

Oxazolidinones as TarO inhibitors

Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a &#x3b2;-lactam antibiotic. 

Oxazolidinones as taro inhibitors

Carbapenem antibacterial compositions and methods of the treatment

Growing community of inventors

Beachwood, NJ, United States of America

Charles J Gill